Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/30051
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sudha, Thangirala | - |
dc.contributor.author | Bharali, Dhruba J. | - |
dc.contributor.author | Darwish, Noureldien H. E. | - |
dc.contributor.author | Keating, Kelly A. | - |
dc.contributor.author | Lin, Hung-Yun | - |
dc.contributor.author | Davis, Paul J. | - |
dc.contributor.author | Mousa, Shaker A. Shaker A. | - |
dc.date.accessioned | 2022-12-22T11:43:46Z | - |
dc.date.available | 2022-12-22T11:43:46Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | Sudha, T. vd. (2017). ''Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac''. International Journal of Nanomedicine, 12, 1305-1315. | en_US |
dc.identifier.issn | 1178-2013 | - |
dc.identifier.uri | https://doi.org/10.2147/IJN.S123742 | - |
dc.identifier.uri | https://www.dovepress.com/targeted-delivery-of-paclitaxel-and-doxorubicin-to-cancer-xenografts-v-peer-reviewed-fulltext-article-IJN | - |
dc.identifier.uri | http://hdl.handle.net/11452/30051 | - |
dc.description | NanoPharmaceuticals LLC (Rensselaer, NY, USA) | en_US |
dc.description.abstract | The tetraiodothyroacetic acid (tetrac) component of nano-diamino-tetrac (NDAT) is chemically bonded via a linker to a poly(lactic-co-glycolic acid) nanoparticle that can encapsulate anticancer drugs. Tetrac targets the plasma membrane of cancer cells at a receptor on the extracellular domain of integrin alpha v beta 3. In this study, we evaluate the efficiency of NDAT delivery of paclitaxel and doxorubicin to, respectively, pancreatic and breast cancer orthotopic nude mouse xenografts. Intra-tumoral drug concentrations were 5-fold (paclitaxel; P < 0.001) and 2.3-fold (doxorubicin; P < 0.01) higher than with conventional systemic drug administration. Tumor volume reductions reflected enhanced xenograft drug uptake. Cell viability was estimated by bioluminescent signaling in pancreatic tumors and confirmed an increased paclitaxel effect with drug delivery by NDAT. NDAT delivery of chemotherapy increases drug delivery to cancers and increases drug efficacy. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Dove Medical | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Atıf Gayri Ticari Türetilemez 4.0 Uluslararası | tr_TR |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Science & technology - other topics | en_US |
dc.subject | Pharmacology & pharmacy | en_US |
dc.subject | Doxorubicin | en_US |
dc.subject | Integrin | en_US |
dc.subject | Nanoparticle | en_US |
dc.subject | Nanotetrac | en_US |
dc.subject | NDAT | en_US |
dc.subject | Paclitaxel | en_US |
dc.subject | Tetraiodothyroacetic acid | en_US |
dc.subject | Xenografts | en_US |
dc.subject | Activated protein-kinase | en_US |
dc.subject | Tetraiodothyroacetic acid | en_US |
dc.subject | Thyroid-hormone | en_US |
dc.subject | In-vitro | en_US |
dc.subject | Co-delivery | en_US |
dc.subject | Cells | en_US |
dc.subject | Nanomedicine | en_US |
dc.subject | Receptor | en_US |
dc.subject | Growth | en_US |
dc.subject | Cisplatin | en_US |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Antineoplastic agents | en_US |
dc.subject.mesh | Breast neoplasms | en_US |
dc.subject.mesh | Cell line, tumor | en_US |
dc.subject.mesh | Cell survival | en_US |
dc.subject.mesh | Doxorubicin | en_US |
dc.subject.mesh | Drug delivery systems | en_US |
dc.subject.mesh | Dynamic light scattering | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Lactic acid | en_US |
dc.subject.mesh | Mice, nude | en_US |
dc.subject.mesh | Nanoparticles | en_US |
dc.subject.mesh | Paclitaxel | en_US |
dc.subject.mesh | Pancreatic neoplasms | en_US |
dc.subject.mesh | Particle size | en_US |
dc.subject.mesh | Polyglycolic acid | en_US |
dc.subject.mesh | Thyroxine | en_US |
dc.subject.mesh | Xenograft model antitumor assays | en_US |
dc.title | Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac | en_US |
dc.type | Article | en_US |
dc.identifier.wos | 000394048400002 | tr_TR |
dc.identifier.scopus | 2-s2.0-85013472911 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Veteriner Fakültesi/Fizyoloji Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Fen-Edebiyat Fakültesi/Biyoloji Bölümü. | tr_TR |
dc.contributor.orcid | 0000-0002-5600-8162 | tr_TR |
dc.identifier.startpage | 1305 | tr_TR |
dc.identifier.endpage | 1315 | tr_TR |
dc.identifier.volume | 12 | tr_TR |
dc.relation.journal | International Journal of Nanomedicine | en_US |
dc.contributor.buuauthor | Yalçın, Murat | - |
dc.contributor.buuauthor | Coşkun, Melis Debreli | - |
dc.contributor.researcherid | AAG-6956-2021 | tr_TR |
dc.contributor.researcherid | AAF-3992-2020 | tr_TR |
dc.relation.collaboration | Yurt dışı | tr_TR |
dc.identifier.pubmed | 28243091 | tr_TR |
dc.subject.wos | Nanoscience & nanotechnology | en_US |
dc.subject.wos | Pharmacology & pharmacy | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | PubMed | en_US |
dc.wos.quartile | Q2 (Nanoscience & nanotechnology) | en_US |
dc.wos.quartile | Q1 (Pharmacology & pharmacy) | en_US |
dc.contributor.scopusid | 57192959734 | tr_TR |
dc.contributor.scopusid | 57193066146 | tr_TR |
dc.subject.scopus | Integrin; Thyroid Hormones; Nano-Diamino-Tetrac | en_US |
dc.subject.emtree | Diamino tetraiodothyroacetic acid nanoparticle | en_US |
dc.subject.emtree | Docetaxel | en_US |
dc.subject.emtree | Doxorubicin | en_US |
dc.subject.emtree | Nanoparticle | en_US |
dc.subject.emtree | Paclitaxel | en_US |
dc.subject.emtree | Unclassified drug | en_US |
dc.subject.emtree | Antineoplastic agent | en_US |
dc.subject.emtree | Doxorubicin | en_US |
dc.subject.emtree | Lactic acid | en_US |
dc.subject.emtree | Nanoparticle | en_US |
dc.subject.emtree | Paclitaxel | en_US |
dc.subject.emtree | Polyglycolic acid | en_US |
dc.subject.emtree | Polylactic acid-polyglycolic acid copolymer | en_US |
dc.subject.emtree | Tetraiodothyroacetic acid | en_US |
dc.subject.emtree | Thyroxine | en_US |
dc.subject.emtree | Animal cell | en_US |
dc.subject.emtree | Animal experiment | en_US |
dc.subject.emtree | Animal model | en_US |
dc.subject.emtree | Animal tissue | en_US |
dc.subject.emtree | Antineoplastic activity | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Breast cancer | en_US |
dc.subject.emtree | Cell viability | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Drug adsorption | en_US |
dc.subject.emtree | Drug delivery system | en_US |
dc.subject.emtree | Drug efficacy | en_US |
dc.subject.emtree | Drug formulation | en_US |
dc.subject.emtree | Drug uptake | en_US |
dc.subject.emtree | Ex vivo study | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Mouse | en_US |
dc.subject.emtree | Nanoencapsulation | en_US |
dc.subject.emtree | Nonhuman | en_US |
dc.subject.emtree | Pancreas cancer | en_US |
dc.subject.emtree | Particle size | en_US |
dc.subject.emtree | Tumor volume | en_US |
dc.subject.emtree | Analogs and derivatives | en_US |
dc.subject.emtree | Animal | en_US |
dc.subject.emtree | Breast Neoplasms | en_US |
dc.subject.emtree | Cell survival | en_US |
dc.subject.emtree | Chemistry | en_US |
dc.subject.emtree | Drug effects | en_US |
dc.subject.emtree | Drug screening | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Nude mouse | en_US |
dc.subject.emtree | Pancreatic Neoplasms | en_US |
dc.subject.emtree | Photon correlation spectroscopy | en_US |
dc.subject.emtree | Tumor cell line | en_US |
dc.subject.emtree | In vivo study | en_US |
Appears in Collections: | Scopus Web of Science |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Yalçın_vd_2017.pdf | 1.51 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License